Lung Cancer Research Review, Issue 39

In this issue:

Survival advantage with nivolumab in previously treated NSCLC
Predicting response to ICIs in EGFR-mutated NSCLC
Gefitinib ± pemetrexed + carboplatin in EGFR-mutated NSCLC
RRx-001 then platinum + etoposide in previously treated SCLC
LMWH: no survival advantage in a lung cancer trial
ECOG-ACRIN 5508: pemetrexed + bevacizumab maintenance therapy
Assessing biopsy sampling for predicting histology in diffuse MPM
Adding cediranib to platinumpemetrexed in unresectable MPM

Please login below to download this issue (PDF)